Pen Needle, Diabetic
Brand name: Ultra-Fine Mini Pen Needle
Rank #153 of 500 drugs by total cost
$105.0M
Total Cost
1,305,150
Total Claims
$105.0M
Total Cost
57,183
Prescribers
$80
Cost per Claim
237,301
Beneficiaries
2,723,440
30-Day Fills
$1,837
Avg Cost/Provider
23
Avg Claims/Provider
About Pen Needle, Diabetic
Pen Needle, Diabetic (sold as Ultra-Fine Mini Pen Needle) was prescribed 1,305,150 times by 57,183 Medicare Part D providers in 2023, costing the program $105.0M. At $80 per claim, this is a relatively affordable medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 150 | Axitinib (Inlyta) | $109.1M | 5,937 |
| 151 | Ipratropium/Albuterol Sulfate (Combivent Respimat) | $108.3M | 353,594 |
| 152 | Relugolix (Orgovyx) | $107.3M | 38,821 |
| 153 | Pen Needle, Diabetic (Ultra-Fine Mini Pen Needle) | $105.0M | 1,305,150 |
| 154 | Divalproex Sodium (Divalproex Sodium) | $103.4M | 1,921,840 |
| 155 | Nilotinib Hcl (Tasigna) | $100.9M | 6,308 |
| 156 | Quetiapine Fumarate (Quetiapine Fumarate) | $100.9M | 3,820,737 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology